Table 1.

Summary of the effects of Siglec targeting in mouse models of disease.

Disease Model	Siglec Targeted	Mouse Strain	Effect
Anaphylaxis	Human CD33 (Siglec-3)	hCD33 knock-in	Suppresses mast cell activation and protects against anaphylaxis (Duan et al., 2019)
	Siglec-6	Humanized	Protects against anaphylaxis and reduces mast cell-derived mediators (Schanin et al., 2022)
	Siglec-8	Siglec-8 knock-in and humanized	Suppresses mast cell activation and protects against anaphylaxis (Duan et al., 2021; Youngblood et al., 2019b)
Allergic asthma	Siglec-F	Wild type vs. Siglecf−/−, St3gal3−/−, Muc5bΔ/Δ	Lack of Siglec-F or its ligands exacerbate blood, bone marrow, and airway eosinophilia (Kiwamoto et al., 2014; Kiwamoto et al., 2015; Suzukawa et al., 2013; Zhang et al., 2007)
Allergen-induced eosinophilic inflammation	Siglec-F	Wild type	Anti-Siglec-F Ab administration decreases blood and tissue eosinophil numbers and ameliorates disease severity (Camilleri et al., 2021; Rubinstein et al., 2011; Song et al., 2009a; Song et al., 2009b)
EGIDs	Siglec-8	Siglec-8 transgenic	Reduces blood and tissue eosinophil numbers, diminishes type-2 inflammatory cytokines and chemokines, reduces mast cell GI infiltration (Youngblood et al., 2019a)
IL-33-mediated inflammation	Siglec-8	Siglec-8 transgenic	Reduces neutrophil and eosinophil infiltration, decreases inflammatory mediators (Schanin et al., 2020)
TLR-mediated inflammation, viral infection	Siglec-8	Siglec-8 transgenic	Reduces airway inflammation and protects against virus-induced pathology (Gebremeskel et al., 2021)